Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Canales-Albendea, M. A. (Miguel Ángel) | - |
dc.creator | López-Sendón, J.L. (J. L.) | - |
dc.creator | Álvarez-Ortega, C. (Carlos) | - |
dc.creator | Zamora-Auñon, P. (Pilar) | - |
dc.creator | Buño-Soto, A. (Antonio) | - |
dc.creator | Lyon, A.R. (Alexander R.) | - |
dc.creator | Farmakis, D. (Dimitrios) | - |
dc.creator | Cardinale, D. (Daniela) | - |
dc.creator | Feliu-Batlle, J. (Jaime) | - |
dc.creator | Rodríguez-Rodríguez, I. (Isabel) | - |
dc.creator | Rodríguez-Fraga, O. (Olaia) | - |
dc.creator | Albaladejo, A. (Ainara) | - |
dc.creator | Mediavilla, G. (Guimoar) | - |
dc.creator | González-Juanatey, J. R. (José Ramón) | - |
dc.creator | Martínez-Monzonis, A. (Amparo) | - |
dc.creator | Gómez-Prieto, P. (Pilar) | - |
dc.creator | González-Costello, J. (José) | - |
dc.creator | Serrano-Antolín, J. M. (José María) | - |
dc.creator | Cadenas-Chamorro, R. (Rosalía) | - |
dc.creator | López-Fernández, T. (Teresa) | - |
dc.date.accessioned | 2024-01-29T07:49:15Z | - |
dc.date.available | 2024-01-29T07:49:15Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Canales-Albendea, M. A. (Miguel Ángel); López-Sendón, J.L. (J. L.); Álvarez-Ortega, C. (Carlos); et al. "Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry". European Heart Journal. 41 (18), 2020, 1720 - 1729 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10171/68603 | - |
dc.description.abstract | Aim: Cardiotoxicity (CTox) is a major side effect of cancer therapies, but uniform diagnostic criteria to guide clinical and research practices are lacking. Methods and results: We prospectively studied 865 patients, aged 54.7 ± 13.9; 16.3% men, scheduled for anticancer therapy related with moderate/high CTox risk. Four groups of progressive myocardial damage/dysfunction were considered according to current guidelines: normal, normal biomarkers (high-sensitivity troponin T and N-terminal natriuretic pro-peptide), and left ventricular (LV) function; mild, abnormal biomarkers, and/or LV dysfunction (LVD) maintaining an LV ejection fraction (LVEF) ≥50%; moderate, LVD with LVEF 40–49%; and severe, LVD with LVEF ≤40% or symptomatic heart failure. Cardiotoxicity was defined as new or worsening of myocardial damage/ventricular function from baseline during follow-up. Patients were followed for a median of 24 months. Cardiotoxicity was identified in 37.5% patients during follow-up [95% confidence interval (CI) 34.22–40.8%], 31.6% with mild, 2.8% moderate, and 3.1% with severe myocardial damage/dysfunction. The mortality rate in the severe CTox group was 22.9 deaths per 100 patients-year vs. 2.3 deaths per 100 patients-year in the rest of groups, hazard ratio of 10.2 (95% CI 5.5–19.2) (P < 0.001). Conclusions: The majority of patients present objective data of myocardial injury/dysfunction during or after cancer therapy. Nevertheless, severe CTox, with a strong prognostic relationship, was comparatively rare. This should be reflected in protocols for clinical and research practices. | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III (PI13/00559) | es_ES |
dc.language.iso | spa | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Cardiotoxicity | es_ES |
dc.subject | Chemotherapy | es_ES |
dc.subject | Myocardial injury | es_ES |
dc.subject | Left ventricular dysfunction | es_ES |
dc.subject | Heart failure | es_ES |
dc.subject | Cardio-oncology | es_ES |
dc.subject | Radiotherapy | es_ES |
dc.title | Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://academic.oup.com/eurheartj/article/41/18/1720/5721502?login=true | es_ES |
dc.editorial.note | Copyright © 2020, Published on behalf of the European Society of Cardiology. | es_ES |
dadun.citation.endingPage | 1729 | es_ES |
dadun.citation.number | 18 | es_ES |
dadun.citation.publicationName | European Heart Journal | es_ES |
dadun.citation.startingPage | 1720 | es_ES |
dadun.citation.volume | 41 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.